NRD
AMRX icon

Nebula Research & Development’s Amneal Pharmaceuticals AMRX Stock Holding History

Nebula Research & Development’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-121,599
Closed -$984K – 52
2025
Q2 		$984K Buy
121,599
+65,236
+116% +$492K 0.08% 406
2025
Q1 		$472K Buy
56,363
+9,851
+21% +$82.2K 0.04% 625
2024
Q4 		$368K Buy
+46,512
New +$390K 0.04% 656
2024
Q3 		– Sell
-119,284
Closed -$757K – 922
2024
Q2 		$757K Buy
119,284
+22,501
+23% +$143K 0.12% 297
2024
Q1 		$587K Buy
96,783
+55,589
+135% +$313K 0.13% 304
2023
Q4 		$250K Buy
41,194
+28,155
+216% +$125K 0.08% 487
2023
Q3 		$55K Buy
+13,039
New +$48.6K 0.03% 472

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Nebula Research & Development's AMRX Position: Q3 2025 in Review

Nebula Research & Development sold out of Amneal Pharmaceuticals (AMRX) in Q3 2025, closing a stake of 121,599 shares — an estimated $984K sold.

Nebula Research & Development first reported a position in AMRX in Q3 2023 and held it in 7 quarters. The position peaked at $984K in Q2 2025. 248 funds tracked by Wall St. Rank hold AMRX as of Q3 2025.

  • Nebula Research & Development reported no remaining Amneal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 121,599 Amneal Pharmaceuticals shares in Q3 2025, an estimated $984K.
  • Nebula Research & Development first reported a position in Amneal Pharmaceuticals in Q3 2023 and held it in 7 quarters.
  • Nebula Research & Development's Amneal Pharmaceuticals position peaked at $984K in Q2 2025.
  • 248 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.